thalidomide has been researched along with Bone Cancer in 28 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results suggest that thalidomide can efficiently alleviate bone cancer pain and it may be a useful alternative or adjunct therapy for bone cancer pain." | 7.76 | Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-α expression in a mouse model. ( Gu, X; Ma, Z; Mei, F; Ren, B; Zhang, J; Zhang, R; Zheng, Y, 2010) |
| "Thalidomide has been reported to have antitumor activity for treating metastatic hepatocellular carcinoma (HCC)." | 7.73 | Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study. ( Bang, SM; Cho, EK; Han, SH; Kim, JH; Kim, KK; Kim, SS; Kwon, OS; Kwon, SY; Lee, JH; Lee, JJ; Lee, JN; Nam, E; Park, SH; Park, YH; Shin, DB, 2006) |
| "Thalidomide was added to osteosarcoma cells and studied by cytotoxicity assay, evaluating apoptosis, cell cycle arrest, mitochondrial membrane potential (ΔΨm), and reactive oxygen species (ROS) levels and the expression of Bcl‑2, Bax, caspase‑3 and NF‑κB." | 5.43 | Anticancer effect of thalidomide in vitro on human osteosarcoma cells. ( Guo, Q; Liu, S; Liu, Y; Wang, Y; Wu, Y; Xu, H; Yang, Y; Zhang, G; Zhu, J, 2016) |
| "The purpose of the study was to evaluate the efficacy and safety of a bone-targeted regimen consisting of zoledronate, thalidomide, and interferon-gamma in patients with renal cell carcinoma and bone metastases." | 5.12 | Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. ( Do, KA; Jonasch, E; Lin, P; Lin, SH; Mathew, P; Pagliaro, LC; Rhines, L; Siefker-Radtke, A; Tannir, N; Tibbs, R; Tu, SM, 2006) |
| " The tandem transplant trial, Total Therapy 2, enrolled 668 patients, who were randomised up-front to thalidomide (THAL) or no THAL; 56 patients were identified as having had, for at least 6 months prior to initiation of therapy, monoclonal gammopathy of undetermined significance (MGUS, n = 21), smouldering MM (SMM, n = 22) or solitary plasmacytoma of bone (SPC, n = 13)." | 5.12 | Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. ( Anaissie, E; Arzoumanian, V; Barlogie, B; Bolejack, V; Crowley, J; Epstein, J; Hollmig, K; Krishna, S; Pineda-Roman, M; Shaughnessy, JD; van Rhee, F; Walker, R; Zangari, M, 2007) |
| "These results suggest that thalidomide can efficiently alleviate bone cancer pain and it may be a useful alternative or adjunct therapy for bone cancer pain." | 3.76 | Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-α expression in a mouse model. ( Gu, X; Ma, Z; Mei, F; Ren, B; Zhang, J; Zhang, R; Zheng, Y, 2010) |
| "Thalidomide has been reported to have antitumor activity for treating metastatic hepatocellular carcinoma (HCC)." | 3.73 | Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study. ( Bang, SM; Cho, EK; Han, SH; Kim, JH; Kim, KK; Kim, SS; Kwon, OS; Kwon, SY; Lee, JH; Lee, JJ; Lee, JN; Nam, E; Park, SH; Park, YH; Shin, DB, 2006) |
| "Thalidomide was administered as a therapeutic agent for chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in a patient with breast cancer." | 3.69 | Thalidomide-induced perioral neuropathy. ( Elad, S; Galili, D; Garfunkel, AA; Or, R, 1997) |
| "Metastatic renal cell cancer is one of the immuno-sensitive tumors." | 2.71 | Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. ( Bex, A; Boogerd, W; de Gast, GC; Dewit, L; Haanen, JB; Kerst, JM; Mallo, H; Teertstra, HJ, 2005) |
| "Hormone refractory prostate cancer (HRPC) remains a challenge in the management of prostate cancer patients." | 2.42 | Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges. ( Carducci, MA; Rosenbaum, E, 2003) |
| "Multiple myeloma is a haematological disease caused by proliferation of malignant plasma cells in bone marrow." | 1.46 | A case of multiple myeloma with navicular bone involvement. ( Canoz, O; Eser, B; Kaynar, L; Tiren, N; Yildizhan, E, 2017) |
| "Progression to multiple myeloma is the most common pattern of relapse." | 1.46 | Metachronous solitary plasmacytoma. ( Khosa, R; Nangia, S; Seth, S, 2017) |
| "Thalidomide was added to osteosarcoma cells and studied by cytotoxicity assay, evaluating apoptosis, cell cycle arrest, mitochondrial membrane potential (ΔΨm), and reactive oxygen species (ROS) levels and the expression of Bcl‑2, Bax, caspase‑3 and NF‑κB." | 1.43 | Anticancer effect of thalidomide in vitro on human osteosarcoma cells. ( Guo, Q; Liu, S; Liu, Y; Wang, Y; Wu, Y; Xu, H; Yang, Y; Zhang, G; Zhu, J, 2016) |
| "Zoledronic acid was given to both patients by 15 minutes intravenous infusion followed by hemodialysis 24 hours later." | 1.35 | [Zoledronic acid for bone metastases due to advanced renal cell carcinoma under chronic hemodialysis--a report of two cases]. ( Arima, S; Hayakawa, K; Hoshinaga, K; Kusaka, M; Maruyama, T; Miyakawa, S; Mori, S; Sasaki, H; Shiroki, R, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 17 (60.71) | 29.6817 |
| 2010's | 9 (32.14) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Mouhieddine, TH | 1 |
| Barlogie, B | 2 |
| Teruya-Feldstein, J | 1 |
| Pramanik, R | 1 |
| Agarwala, S | 1 |
| Gupta, YK | 1 |
| Thulkar, S | 1 |
| Vishnubhatla, S | 1 |
| Batra, A | 1 |
| Dhawan, D | 1 |
| Bakhshi, S | 1 |
| Tian, C | 1 |
| Yang, H | 1 |
| Zhu, L | 1 |
| Zhang, Q | 1 |
| Cao, Z | 1 |
| Zhang, Y | 1 |
| Yildizhan, E | 1 |
| Kaynar, L | 1 |
| Tiren, N | 1 |
| Canoz, O | 1 |
| Eser, B | 1 |
| Khosa, R | 1 |
| Seth, S | 1 |
| Nangia, S | 1 |
| Zhu, J | 1 |
| Yang, Y | 1 |
| Liu, S | 1 |
| Xu, H | 1 |
| Wu, Y | 1 |
| Zhang, G | 1 |
| Wang, Y | 2 |
| Liu, Y | 1 |
| Guo, Q | 1 |
| Arima, S | 1 |
| Shiroki, R | 1 |
| Mori, S | 1 |
| Maruyama, T | 1 |
| Sasaki, H | 1 |
| Kusaka, M | 1 |
| Miyakawa, S | 1 |
| Hayakawa, K | 1 |
| Hoshinaga, K | 1 |
| Harshman, LC | 1 |
| Li, M | 1 |
| Srinivas, S | 2 |
| Gu, X | 1 |
| Zheng, Y | 1 |
| Ren, B | 1 |
| Zhang, R | 1 |
| Mei, F | 1 |
| Zhang, J | 1 |
| Ma, Z | 1 |
| Chay, WY | 1 |
| Teo, M | 1 |
| Sittampalam, K | 1 |
| Toh, HC | 1 |
| Saboo, SS | 1 |
| Fennessy, F | 1 |
| Benajiba, L | 1 |
| Laubach, J | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Rezvani, H | 1 |
| Haghighi, S | 1 |
| Ghadyani, M | 1 |
| Attarian, H | 1 |
| Lackner, H | 1 |
| Urban, C | 1 |
| Dornbusch, HJ | 1 |
| Schwinger, W | 1 |
| Kerbl, R | 1 |
| Sovinz, P | 1 |
| Mohla, S | 1 |
| Weilbacher, KN | 1 |
| Cher, ML | 1 |
| Oyajobi, BO | 1 |
| Poznak, CV | 1 |
| Clohisy, DR | 1 |
| Rosenbaum, E | 1 |
| Carducci, MA | 1 |
| Jung, W | 1 |
| Zettl, F | 1 |
| Schroers, R | 1 |
| Staehler, M | 1 |
| Rohrmann, K | 1 |
| Bachmann, A | 1 |
| Zaak, D | 1 |
| Stief, CG | 1 |
| Siebels, M | 1 |
| Kerst, JM | 1 |
| Bex, A | 1 |
| Mallo, H | 1 |
| Dewit, L | 1 |
| Haanen, JB | 1 |
| Boogerd, W | 1 |
| Teertstra, HJ | 1 |
| de Gast, GC | 1 |
| Gaur, S | 1 |
| Oo, TH | 1 |
| Aish, LS | 1 |
| Mansoor, S | 1 |
| Frank, RC | 1 |
| Kaplan, F | 1 |
| Nair, S | 1 |
| Guardino, AE | 1 |
| Tsai, YC | 1 |
| Wu, CT | 1 |
| Hong, RL | 1 |
| Ural, AU | 1 |
| Avcu, F | 1 |
| Tannir, N | 1 |
| Jonasch, E | 1 |
| Pagliaro, LC | 1 |
| Mathew, P | 1 |
| Siefker-Radtke, A | 1 |
| Rhines, L | 1 |
| Lin, P | 1 |
| Tibbs, R | 1 |
| Do, KA | 1 |
| Lin, SH | 1 |
| Tu, SM | 1 |
| Pineda-Roman, M | 1 |
| Bolejack, V | 1 |
| Arzoumanian, V | 1 |
| Anaissie, E | 1 |
| van Rhee, F | 1 |
| Zangari, M | 1 |
| Walker, R | 1 |
| Hollmig, K | 1 |
| Shaughnessy, JD | 1 |
| Epstein, J | 1 |
| Krishna, S | 1 |
| Crowley, J | 1 |
| Pauzner, R | 1 |
| Mayan, H | 1 |
| Waizman, A | 1 |
| Rozenman, J | 1 |
| Farfel, Z | 1 |
| Han, SH | 1 |
| Park, SH | 1 |
| Kim, JH | 2 |
| Lee, JJ | 1 |
| Kwon, SY | 1 |
| Kwon, OS | 1 |
| Kim, SS | 1 |
| Kim, KK | 1 |
| Park, YH | 1 |
| Lee, JN | 1 |
| Nam, E | 1 |
| Bang, SM | 1 |
| Cho, EK | 1 |
| Shin, DB | 1 |
| Lee, JH | 1 |
| Elad, S | 1 |
| Galili, D | 1 |
| Garfunkel, AA | 1 |
| Or, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low Dose Chemotherapy (Metronomic Therapy) Versus Best Supportive Care in Progressive and/or Refractory Pediatric Malignancies: a Double Blind Placebo Controlled Randomized Study[NCT01858571] | Phase 3 | 108 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thalidomide and Bone Cancer
| Article | Year |
|---|---|
Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcitriol; C | 2003 |
Therapeutic approaches in metastatic renal cell carcinoma.
Topics: Adrenalectomy; Angiogenesis Inhibitors; Bone Marrow Transplantation; Bone Neoplasms; Cancer Vaccines | 2005 |
7 trials available for thalidomide and Bone Cancer
| Article | Year |
|---|---|
Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy P | 2017 |
The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Renal | 2008 |
Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Fre | 2012 |
Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; | 2005 |
A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Double-Blin | 2005 |
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neopla | 2006 |
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Moda | 2007 |
19 other studies available for thalidomide and Bone Cancer
| Article | Year |
|---|---|
Hemophagocytic relapsed intramedullary plasmacytoma.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bo | 2020 |
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B | 2017 |
A case of multiple myeloma with navicular bone involvement.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Immunologic Factors; | 2017 |
Metachronous solitary plasmacytoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Diphosphonates; Di | 2017 |
Anticancer effect of thalidomide in vitro on human osteosarcoma cells.
Topics: Angiogenesis Inhibitors; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Shape; Drug Screening Ass | 2016 |
[Zoledronic acid for bone metastases due to advanced renal cell carcinoma under chronic hemodialysis--a report of two cases].
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Carcinoma, Renal Cell; Chronic Dise | 2008 |
Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-α expression in a mouse model.
Topics: Animals; Behavior, Animal; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Injections, Int | 2010 |
Effective use of thalidomide in the treatment of recurrent metastatic chordoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Chordoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Loc | 2011 |
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Cyclophos | 2012 |
Interferon alfa-2a in recurrent metastatic hemangiopericytoma.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2003 |
Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessions.
Topics: Animals; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Cell Transformation, Neoplastic; Clinical Tr | 2003 |
[Multiple myeloma -- therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined | 2005 |
Gastric relapse of solitary bone plasmacytoma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combin | 2005 |
Response of carcinoma of unknown primary site affecting bone to thalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Dexamethasone; Humans; Ma | 2005 |
Response of refractory osteosarcoma to thalidomide and celecoxib.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Celecoxib; Drug Resistance, Neoplasm | 2005 |
Bisphosphonates may potentiate effects of thalidomide-dexamethasone combination in advanced multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dexamethasone; Diphosphonates; Human | 2006 |
Successful thalidomide treatment of persistent chylous pleural effusion in disseminated lymphangiomatosis [corrected].
Topics: Angiogenesis Inhibitors; Bone Neoplasms; Chylothorax; Female; Humans; Lymphangiomyoma; Middle Aged; | 2007 |
Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study.
Topics: Adult; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Immunosuppressi | 2006 |
Thalidomide-induced perioral neuropathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adju | 1997 |